Results of Treatment and Prognostic Factors of Lymphoblastic Leukemia: An Analysis in 33 Patients

Cho, You Sook; Lee, Kyoo Hyung; Lee, Je Hwan; Kim, Sung Bae; Kim, Sang We; Suh, Cheol Won; Lee, Jung Shin; Kim, Woo Kun; Kim, Sang Hee; Chi, Hyun Sook; Park, Chan Jung

Abstract

OBJECTIVES
Rate of complete remission and long-term survival in adult acute lymphoblastic leukemia group has not been as satisfactory as that in childhood ALL. Recently introduction of induction chemotherapy of more intensive combination and various trials of postremission therapy are making improved results better looked forward to. And subtypes of ALL according to the degree of differentiation into T and B cells are identified by using immunologic markers hopefully to work out proper treatment for each subtype.
METHODS
We analited results of treatment and differences of complete remission rate, remission duration and overall survival as to various immunologic markers and clinicopathologic characteristics in 33adult ALL patients.
RESULTS
Eighty five percents of the 27cases that had VPDL chemotherapy achieved complete remission and both overall median survival and mediom duration of remission were 52weeks. No definite prognostic factors were detected influencing complete remission rate, remission duration and overall survival except that patients with serum albumin level higher than 4.0mg/dL showed highter complete remission rate. Although mature B-ALL showed the shortest overall median survival, degree of differenciation of B-cell and other immunologic markers did not influence on complete remission rate, remission duration or overall survival.
CONCLUSION
Further studies are needed to delire the prognostic factors in adult ALL.